Clinical Study
Lessons from Laparoscopic Liver Surgery: A Nine-Year Case Series
Table 1
Demographic, intraoperative, and postoperative details of patients undergoing laparoscopic liver surgery.
| Patient | Age | Sex | Procedure | Histology | Operation time | Blood loss | Resection margin | Length of | Complications | (M/F) | (minutes) | (mL) | (mm) | stay (days) |
| 1 | 63 | M | RHH | CRM | 240 | 1500 | 1 | 4 | Nil | 2 | 60 | M | WES3 | HMG | 240 | 0 | CE | 2 | Nil | 3 | 51 | F | WES5 | LCA | 120 | 0 | CE | 3 | Nil | 4 | 68 | F | S5/6R | CRM | 240 | 0 | CE | 5 | Nil | 5 | 74 | F | S4R | CRM | 180 | 0 | 22 | 3 | Nil | 6 | 69 | M | S6R | CRM | 105 | 0 | 5 | 3 | Nil | 7 | 74 | M | S5R+RIH | CRM | 180 | 0 | CE | 7 | Nil | 8 | 43 | F | S2R | FNH | 120 | 0 | CE | 3 | Nil | 9 | 75 | M | S3R | CRM | 240 | 0 | 10 | 3 | Nil | 10 | 82 | M | LLB | CRM | 180 | 500 | CE | 4 | Nil | 11 | 77 | M | MAS4/8 | HCC | 150 | 0 | CE | 6 | Nil | 12 | 45 | F | WES6 | HMG | 180 | 0 | 45 | 6 | Nil | 13 | 64 | M | LLB | CRM | 240 | 0 | 10 | 4 | Nil | 14 | 73 | M | S6R | CRM | 240 | 600 | 4 | 6 | Nil | 15 | 73 | M | WES6, MAS5 | HMG | 90 | 0 | CE | 4 | Nil | 16 | 70 | M | MAS4a | HCC | 90 | 0 | N/A | 7 | Nil | 17 | 69 | M | S5R | CRM | 210 | 500 | CE | 10 | Nil | 18 | 57 | F | WES5 | HMG | 120 | 0 | CE | 2 | Convert to open due to CUSA failure | 19 | 36 | F | LLB | FNH | 120 | 0 | CE | 3 | Nil | 20 | 34 | F | LLB,MAS4 | FNH | 120 | 0 | CE | 3 | Nil | 21 | 55 | M | MAS7 | HMG | 90 | 0 | N/A | 2 | Nil | 22 | 58 | F | WES3 SOC | LC | 90 | 0 | CE | 2 | Nil | 23 | 38 | M | EL: (Planned RHH aborted) | CRM Peritoneal deposits | 90 | 0 | N/A | 2 | Nil | 24 | 51 | M | WES2/3 | HMG | 120 | 0 | CE | 3 | Nil | 25 | 47 | F | WE2/3 | Angiomyo-leiyoma | 60 | 0 | CE | 2 | Nil | 26 | 52 | F | WES3 | Mucinous cystaden-oma | 60 | 0 | CE | 1 | Nil | 27 | 62 | F | LDBDC, SOC | Biliary cystaden-oma | 40 | 0 | N/A | 2 | Nil | 28 | 41 | F | LDLC | LC | 40 | 0 | N/A | 2 | Nil | 29 | 73 | F | LDLC | LC | 60 | 0 | N/A | 1 | Nil | 30 | 57 | F | LDBDC, SOC | BDC | 60 | 0 | N/A | 2 | Nil | 31 | 56 | F | LDLC, SOC | LC | 60 | 0 | N/A | 1 | Nil | 32 | 84 | M | S5R | CRM | 60 | 10 | CE | 1 | Nil | 33 | 42 | F | LDPCL | LCPCL | 30 | 0 | N/A | 3 | Nil | 34 | 79 | M | LDPCL | LCPCL | 60 | 0 | N/A | 3 | Nil | 35 | 71 | F | MAS4 | HCC | 40 | 0 | N/A | 2 | Nil | 36 | 32 | F | WES5/6 | FNH | 120 | 0 | 30 | 3 | Nil | 37 | 43 | F | MAS4 | Parathyro-ID carcinoma metastasis | 60 | 0 | N/A | 1 | Nil | 38 | 51 | F | WES6 | HMG | 120 | 0 | 20 | 3 | Nil | 39 | 72 | F | S4/S6R | CRM | 200 | 0 | 4 | 3 | Nil | 40 | 34 | F | MA | FNH | 130 | 0 | N/A | 2 | Nil |
|
|